MAS related GPR family member X10, pseudogeneGenealiases: []
Q-omics provides the consensus-scored MRGPRX10P profile across patient tissues and cancer cell-line models. MRGPRX10P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MRGPRX10P is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MRGPRX10P RNA expression shows 5,717 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, LUSC, and STAD as cancer lineages where MRGPRX10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRGPRX10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRGPRX10P survival associations across molecular data types. MRGPRX10P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRGPRX10P RNA expression–survival associations across cancer types. High MRGPRX10P expression shows unfavorable associations in THCA, READ, UCS, TGCT, GBM and THYM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MRGPRX10P RNA expression.
This table summarizes MRGPRX10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MRGPRX10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRGPRX10P shows higher tumor expression in LUSC. The LUSC box plot shows higher MRGPRX10P RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .048).
This table shows molecular features associated with MRGPRX10P in patient tissues and cancer cell lines. In patient samples, MRGPRX10P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
